grant
Decoding the Cullin-5 complex to engineer therapeutic T cells with durable effector function
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Sept 2025Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY202520S Catalytic Proteasome20S Core Proteasome20S Proteasome20S ProteosomeAblationAcuteAffectAffinity ChromatographyAntigensAutomobile DrivingBindingCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCIS GeneCIS proteinCIS-1 GeneCIS-1 ProteinCISH ProteinCISH geneCRISPRCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas systemCRISPR/Cas9 screenCUL-5Cancer PatientCancer TreatmentCancersCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCellular FunctionCellular PhysiologyCellular ProcessChronicClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplexCullin 5Cullin 5 ProteinCullin Homolog 5Cytokine Inducible SH2-Containing ProteinCytokine Signal TransductionCytokine SignalingCytokine-Inducible Inhibitor of Signaling Type 1BCytokine-Inducible Inhibitor of Signaling Type 1B GeneCytokine-Inducible SH2-Containing Protein GeneDataDevelopmentDisablingDysfunctionE3 LigaseE3 Ubiquitin LigaseEducational process of instructingEffectivenessEngineeringFailureFamilyFunctional disorderFuture GenerationsG18G18 GeneGeneticGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenomeGoalsHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHumanImmunocompetentIntracellular Communication and SignalingKnock-outKnockoutKnowledgeMacropainMacroxyproteinaseMalignant CellMalignant Hematologic NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMapsMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMediatingMediatorMedicineModelingModern ManMolecular InteractionMulticatalytic ProteinaseOncologyOncology CancerPhenotypePhysiopathologyPlayPost Translational Modification AnalysisPre-Clinical ModelPreclinical ModelsProsomeProteasomeProteasome Endopeptidase ComplexProteomicsProteosomeReceptor ProteinRecombinant DNA TechnologyResearchRoleSOCS GeneSafetySignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSubcellular ProcessSuppressor of Cytokine SignalingSuppressor of Cytokine Signaling GeneT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell DevelopmentT-Cell OntogenyT-CellsT-LymphocyteT-Lymphocyte DevelopmentT-cell therapeuticsT-cell transfer therapyTeachingTeff cellTestingTherapeuticTreatment EfficacyTumor AntigensTumor BurdenTumor LoadTumor-Associated AntigenUbiquitilationUbiquitin Protein LigaseUbiquitin-Protein Ligase ComplexesUbiquitin-Protein Ligase E3UbiquitinationUbiquitinoylationVasopressin-Activated Calcium-Mobilizing ReceptorVasopressin-Activated Calcium-Mobilizing Receptor-1adoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyaffinity purificationanti-cancer therapybase editorbiological signal transductioncancer antigenscancer cellcancer microenvironmentcancer therapycancer-directed therapychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclustered regularly interspaced short palindromic repeats screencytokinedevelopmentaldrivingeffector T cellengineered T cellsexhaustfitnessgene editing platformgene editing systemgene editing technologygene editing toolsgene manipulationgene-editing toolkitgenetic manipulationgenetically engineeredgenetically engineered T-cellsgenetically manipulategenetically perturbgenome scalegenome-widegenomewideimmune competentimmunogenimprovedin vivoinsightintervention efficacyleukemia/lymphomalymphoma/leukemiamalignancymodel designmouse modelmulticatalytic endopeptidase complexmurine modelneoplasm/cancernext generationnucleasepathophysiologypre-clinicalpreclinicalpreservationpressurepreventpreventingprogramsreceptorresponserestraintsocial rolestemsuccesssynergismtherapeutic T-cell platformtherapeutic efficacytherapy efficacythymus derived lymphocytetooltransgenic T- cellstumortumor microenvironmenttumor-specific antigenubiquinationubiquitin conjugationubiquitin-protein ligase
Description preview
Background: T cell therapies represent one of the most promising recent developments in oncology, with
impressive responses in certain leukemias and lymphomas resulting in the FDA approval of six CAR-T cell
therapies. However, it has become increasingly clear that there are numerous challenges to the successful
application of these therapies to a…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click